Zenas BioPharma Inc. (NASDAQ: ZBIO) announced that results from its Phase 3 INDIGO trial evaluating obexelimab for Immunoglobulin G4-Related Disease ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE